GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Revolution Beauty Group PLC (LSE:REVB) » Definitions » Net Change in Cash

Revolution Beauty Group (LSE:REVB) Net Change in Cash : £-3.7 Mil (TTM As of Aug. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Revolution Beauty Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Revolution Beauty Group's Net Change in Cash for the six months ended in Aug. 2023 was £-3.0 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Aug. 2023 was £-3.7 Mil.

Revolution Beauty Group Net Change in Cash Historical Data

The historical data trend for Revolution Beauty Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Beauty Group Net Change in Cash Chart

Revolution Beauty Group Annual Data
Trend Dec17 Dec18 Dec19 Feb22 Feb23
Net Change in Cash
- -3.17 5.74 10.04 -4.58

Revolution Beauty Group Semi-Annual Data
Dec18 Dec19 Aug21 Feb22 Aug22 Feb23 Aug23
Net Change in Cash Get a 7-Day Free Trial 16.22 -6.18 -3.87 -0.71 -3.04

Revolution Beauty Group Net Change in Cash Calculation

Revolution Beauty Group's Net Change in Cash for the fiscal year that ended in Feb. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.061+-8.513+4.698+-0.699
=-4.6

Revolution Beauty Group's Net Change in Cash for the quarter that ended in Aug. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.907+-1.024+-2.301+1.194
=-3.0

Net Change in Cash for the trailing twelve months (TTM) ended in Aug. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-3.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revolution Beauty Group Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Revolution Beauty Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Revolution Beauty Group (LSE:REVB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Revolution Beauty Group PLC (LSE:REVB) » Definitions » Net Change in Cash
Comparable Companies
LSE:MCB LSE:ACRL LSE:CRL LSE:BAR LSE:BYOT LSE:CBX LSE:W7L PG XPAR:OR LSE:ULVR BOM:500696 CL LSE:RKT KMB EL KVUE XTER:BEI XTER:HEN3 CHD TSE:8113
Traded in Other Exchanges
8UA:Germany
Address
90 York Way, Kings Place, London, GBR, N1 9AG
Website
https://www.revolutionbeautyplc.com
Revolution Beauty Group PLC is a global mass beauty and personal care business that operates a multi-brand, multi-category strategy and sells its products both DTC via its e-commerce operations, and in both physical and digital retailers through wholesale relationships. It has warehousing facilities in the UK, USA, and Australia, and offices in the UK, USA, New Zealand, and Germany.

Revolution Beauty Group (LSE:REVB) Headlines

From GuruFocus

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress

By GuruFocusNews GuruFocusNews • 07-05-2022

Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease

By Business Wire Business Wire • 10-25-2022

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

By GlobeNewswire GlobeNewswire • 07-23-2022

Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering

By Business Wire Business Wire • 02-13-2023

Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering

By Business Wire Business Wire • 02-09-2023

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

By PurpleRose PurpleRose • 07-12-2022

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

By Business Wire • 06-29-2023

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

By Business Wire • 10-12-2023

Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering

By PurpleRose PurpleRose • 07-29-2022

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

By Business Wire Business Wire • 05-22-2023